SEC Form	4
----------	---

Instruction 1(b).

Г

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

D

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP	OMB Number:	3235-0287	
	Estimated average burden		
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934	hours per response:	0.5	
or Section 30(h) of the Investment Company Act of 1940			

I

				or Se	ction 30(h) of the In	vestme	nt Cor	npany Act of	1940						
1. Name and Address of Reporting Person [*] HEGGIE THERESA				2. Issuer Name and Ticker or Trading Symbol BIOCRYST PHARMACEUTICALS INC [BCRX]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last) 4505 EMPER	(First) OR BOULEVA	(Middle)		3. Dat	e of Earliest Transa	iction (N	/lonth/	Day/Year)			Officer (give title below)	Other below	(specify)		
SUITE 200				4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)				
										X	Form filed by On	e Reporting Per	son		
(Street) DURHAM	NC	27703									Form filed by Mo Person	ore than One Re	porting		
(City)	(State)	(Zip)		Rul	e 10b5-1(c)	Tran	sact	ion Indic	ation						
				Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.											
		Table I - No	n-Deriva	tive S	ecurities Acq	uired,	Dis	posed of,	or Bei	neficially	/ Owned				
Date			2. Transac Date (Month/Da	Execution Date,		3. Transaction Code (Instr. 8)		4. Securities Disposed Of 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned	
(e.g., puts, calls, warrants, options, convertible securities)	

A

870(1)

A

\$6.46

52,730

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of Deriv Secu Acqu (A) of Dispo of (D)	r osed) r. 3, 4	Expiration Date (Month/Day/Year)		Date Amount of			9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

Common Stock

1. Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of \$11,250.

05/31/2024

/s/ Alane P. Barnes, by power	06/03/2024
<u>of attorney</u>	00/03/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.